|
|
| | 11β-13,14-dihydro-15-keto Prostaglandin F2α-d9 Basic information |
| | 11β-13,14-dihydro-15-keto Prostaglandin F2α-d9 Chemical Properties |
| solubility | DMF: 50 mg/ml
DMSO: 50 mg/ml
Ethanol: 50 mg/mlPBS (pH 7.2): 1 mg/ml |
| | 11β-13,14-dihydro-15-keto Prostaglandin F2α-d9 Usage And Synthesis |
| Description | 11β-13,14-dihydro-15-keto Prostaglandin F2α-d9 (11β-13,14-dihydro-15-keto PGF2α-d9) is intended for use as an internal standard for the quantification of 11β-13,14-dihydro-15-keto PGF2α (Item No. 16540) by GC- or LC-MS. 11β-13,14-dihydro-15-keto PGF2α is a metabolite of prostaglandin D2 (PGD2; Item No. 12010) in the 15-hydroxy PGDH pathway.1,2 Infusion or inhalation of tritiated PGD2 in normal males results in the appearance of peak levels of both 11β-PGF2α, as the immediate product, and 11β-13,14-dihydro-15-keto PGF2α in the plasma within 10 minutes.1 Homogenates of human lung metabolize PGD2 first to 11β-PGF2α and then to 11β-15-keto-PGF2α in the presence of NAD+, but not 11β-13,14-dihydro-15-keto PGF2α.2 Guinea pig liver and kidney homogenates metabolize PGD2 to 11β-13,14-dihydro-15-keto PGF2α, via 11β-PGF2α, in the presence of NAD+ and NADP+.2WARNING This product is not for human or veterinary use. | | References | [1] CLIVE ROBINSON Stephen T H Christopher C Hardy. The metabolism of prostaglandin D2 after inhalation or intravenous infusion in normal men[J]. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1988, 963 2: Pages 151-161. DOI: 10.1016/0005-2760(88)90276-7
[2] C. ROBINSON. The metabolism of prostaglandin D2 evidence for the sequential conversion by NADPH and NAD+ dependent pathways[J]. Biochemical pharmacology, 1989, 38 19: Pages 3267-3271. DOI: 10.1016/0006-2952(89)90624-2 |
| | 11β-13,14-dihydro-15-keto Prostaglandin F2α-d9 Preparation Products And Raw materials |
|